OpenAI Acquires Orchestra Bio to Expand Its Drug Development Tools

OpenAI has acquired Orchestra Bio, bringing a drug-program coordination platform into its Rosalind life sciences tools as the company expands its work on AI-assisted drug development.

OpenAI announced the deal Tuesday, Oct. 20, and said Orchestra Bio's team and technology will join Rosalind. Orchestra's software uses AI agents to monitor drug-development studies and track work across programs, while scientists and program leaders make decisions. The agents are designed to show how a change in one area may affect related work, gather relevant information and compare possible responses.

OpenAI aims to build agents that help coordinate the studies and decisions involved in developing potential medicines. The announcement gave no launch date for those planned tools or purchase price.

OpenAI introduced GPT-Rosalind on April 16 as a model for research in biology, chemistry and drug discovery. Rosalind also includes tools for analyzing results and planning experiments; Orchestra adds software designed to coordinate activity across drug programs.